Education
About Us
Working with TipRanks
Follow Us
Hemostemix Inc (TSE:HEM)
:HEM
HEM Stock Chart & Stats
C$0.08
C$0.03(23.81%)
At close: 4:00 PM EST
C$0.08
C$0.03(23.81%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.43
Previous CloseN/A
Volume356.00K
Average Volume (3M)138.35K
Market Cap
C$16.02M
Enterprise ValueC$23.08M
Total Cash (Recent Filing)C$1.30M
Total Debt (Recent Filing)C$3.44M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding188,488,540
10 Day Avg. Volume155,944
30 Day Avg. Volume138,348
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)-1.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hemostemix News
HEM FAQ
What was Hemostemix Inc’s price range in the past 12 months?
Hemostemix Inc lowest stock price was C$0.07 and its highest was C$0.42 in the past 12 months.
What is Hemostemix Inc’s market cap?
Hemostemix Inc’s market cap is C$16.02M.
When is Hemostemix Inc’s upcoming earnings report date?
Hemostemix Inc’s upcoming earnings report date is May 05, 2026 which is in 130 days.
How were Hemostemix Inc’s earnings last quarter?
Hemostemix Inc released its earnings results on Nov 28, 2025. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is Hemostemix Inc overvalued?
According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued.
Does Hemostemix Inc pay dividends?
Hemostemix Inc does not currently pay dividends.
What is Hemostemix Inc’s EPS estimate?
Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix Inc have?
Hemostemix Inc has 188,488,540 shares outstanding.
What happened to Hemostemix Inc’s price movement after its last earnings report?
Hemostemix Inc reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hemostemix Inc?
Currently, no hedge funds are holding shares in TSE:HEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hemostemix Inc
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Technical Analysis
Innovotech
―
Britannia Life Sciences Inc
―
Sirona Biochem
―
PreveCeutical Medical
―
Gemina Laboratories Ltd.
―
Options Prices
Currently, No data available
---